Publications by authors named "T Rolf"

Claim this Profile
S
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Tracey A Day, Adam Penn-Nicholson, Angelique Kany Kany Luabeya, Andrew Fiore-Gartland, Nelita Du Plessis, Tom A Rolf

Lancet Respir Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults.
Malcolm S Duthie, Aude Frevol, Tracey Day, Rhea N Coler, Julie Vergara, Tom Rolf

Vaccine· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of elective percutaneous peripheral revascularization in outpatients: A 10-year single-center experience.
S Malekzadeh, T Rolf, F Doenz, A Chouiter, A-M Jouannic

Diagn Interv Imaging· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
Rhea N Coler, Tracey A Day, Ruth Ellis, Franco M Piazza, Anna Marie Beckmann, Tom Rolf

NPJ Vaccines· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment of a yeast-based VLP platform for antigen presentation.
David Wetzel, Theresa Rolf, Manfred Suckow, Andreas Kranz, Andreas Barbian

Microb Cell Fact· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis